Exemestane
- CAS No.
- 107868-30-4
- Chemical Name:
- Exemestane
- Synonyms
- AROMASIN;EXALAMIDE;Exemestan;ExeMestane(AroMasin);EXE;ROMASIN;Isimetan;PNU155971;FCE-24304;ExeMestine
- CBNumber:
- CB5760314
- Molecular Formula:
- C20H24O2
- Molecular Weight:
- 296.4
- MOL File:
- 107868-30-4.mol
- Modify Date:
- 2024/5/16 17:35:26
| Melting point | 155.13°C |
|---|---|
| Boiling point | 453.7±45.0 °C(Predicted) |
| Density | 1.13±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: ≥20mg/mL |
| form | powder |
| color | white to off-white |
| optical activity | [α]/D +250 to +300°, c = 1 in methanol |
| InChI | InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1 |
| InChIKey | BFYIZQONLCFLEV-DAELLWKTSA-N |
| SMILES | C1(=O)C=C2[C@](C)(C=C1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)C(=O)CC3)CC2=C |
| CAS DataBase Reference | 107868-30-4(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS08,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H360-H411 | |||||||||
| Precautionary statements | P201-P202-P273-P280-P308+P313-P391 | |||||||||
| Hazard Codes | T,N | |||||||||
| Risk Statements | 60-61-51 | |||||||||
| Safety Statements | 53-22-36/37-57 | |||||||||
| WGK Germany | 3 | |||||||||
| HS Code | 29372900 | |||||||||
| NFPA 704 |
|
Exemestane price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | PZ0006 | Exemestane ≥98% (HPLC) | 107868-30-4 | 5MG | ₹14115.8 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PZ0006 | Exemestane ≥98% (HPLC) | 107868-30-4 | 25MG | ₹55218.33 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1634 | Exemestane Pharmaceutical Secondary Standard; Certified Reference Material | 107868-30-4 | 1G | ₹11961.63 | 2022-06-14 | Buy |
Exemestane Chemical Properties,Uses,Production
Description
Exemestane was launched in US and other countries for the treatment of estrogendependent tumors and postmenopausal breast cancer. It is a novel steroidal compound structurally related to the natural substrate for the biosynthesis of estrogen, androstanedione, and can be synthesized by methylidenation of androsta-1, 4-dien- 17beta-ol-3-one in 6 position then oxidation of the alcohol function. Exemestane is an irreversible inactivator of the aromatase enzyme system, so inducing in vivo a dose-related sustained suppression of serum estrogen and minimal endocrine activity. It is the first steroidal representative of the third-generation of orally active aromatase inhibitors with a highly potent and selective mechanism of action, displaying good tolerability and safety profile. In rats with DMBA-induced mammary tumors, 10 to 100 mglkg of exemestan administered po twice-daily for 4 weeks resulted in 76 to 88% regression. In women failing anti-estrogen therapy with tamoxifen, this agent has demonstrated high activity in locally advanced or metastatic disease. In addition, it may also have potential for breast cancer prevention.
Chemical Properties
white to light yellow crystal powder
Uses
Labeled Exemestane, intended for use as an internal standard for the quantification of Exemestane by GC- or LC-mass spectrometry.
Definition
ChEBI: A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced brea t cancer.
General Description
Exemestane, 6-methylenandrosta-1,4-diene-3,17-dione (Aromasin), is the first steroid-basedaromatase inhibitor approved for the treatment of breastcancer in the United States. It is a mechanism-based inactivatorthat irreversibly inhibits the enzyme. Plasma estrogenlevels are reduced by 85% to 95% within 2 to 3 days, and effectslast 4 to 5 days. Exemestane does not inhibit any of themajor cytochromes P450 and has essentially no interactionwith steroid receptors, with only a very weak affinity for theAR. The 17β-hydroxyexemestane reduction product, however,has much higher affinity for the AR than the parent(still several fold less than DHT, 0.28% for parent vs. 30%for metabolite). The clinical significance of the affinity islikely minimal because of the low levels of the metaboliteproduced.
Hazard
A reproductive hazard.
Exemestane Preparation Products And Raw materials
Raw materials
1of4
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Coral Drugs Pvt Ltd | +91-1244518100 +91-8199986118 | New Delhi, India | 24 | 58 | Inquiry |
| Apotex Pharmachem India Pvt Ltd | +91-8022891034 +91-8022891000 | Karnataka, India | 109 | 58 | Inquiry |
| Cipla Ltd | +912224826000 | Maharashtra, India | 133 | 58 | Inquiry |
| Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
| Sun Pharmaceutical Industries Ltd | +91-2242244224 +91-2243244324 | Maharashtra, India | 108 | 58 | Inquiry |
| Gland Chemicals Pvt Ltd | +91-9492733833 +91-9346729196 | Telangana, India | 16 | 58 | Inquiry |
| Sakar Healthcare | +91-8976292690 +91-9967572302 | Gujarat, India | 47 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| Akums Lifesciences Ltd | +91-1147511000 +91-1147511000 | New Delhi, India | 38 | 58 | Inquiry |
| SUN PHARMACEUTICAL INDUSTRIES LTD | (+91 22) 4324 4324 | New Delhi, India | 175 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Coral Drugs Pvt Ltd | 58 |
| Apotex Pharmachem India Pvt Ltd | 58 |
| Cipla Ltd | 58 |
| Hetero Drugs Limited | 58 |
| Sun Pharmaceutical Industries Ltd | 58 |
| Gland Chemicals Pvt Ltd | 58 |
| Sakar Healthcare | 58 |
| Ralington Pharma | 58 |
| Akums Lifesciences Ltd | 58 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 58 |
Related articles
- Exemestane: A Breakthrough Aromatase Inhibitor Treatment for Advanced Breast Cancer
- Exemestane effectively treats hormone-sensitive breast cancer in postmenopausal women, showing superior efficacy and safety in....
- Feb 7，2024
- Exemestane used to treat breast cancer
- Exemestane is an oral steroidal aromatase inhibitor used to treat hormone responsive breast cancers in women who are postmenop....
- Jan 11，2023
- The Applications and Pharmacological effects of Exemestane
- Exemestane is the generic name for the trade name drug Aromasin?. In some cases, health care professionals may use the trade n....
- Aug 20，2019
107868-30-4(Exemestane)Related Search:
1of4
chevron_right